Lawrence Walter

Lawrence Walter is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2010, the company is privately held and operates under the Corporate Identification Number (CIN) U45201MH2010PTC207702. The registered office is located at 1, La Petite Fleur, Gautam Buddha Marg, Opp. Orlem Church, Malad (W) Mumbai 400064, Maharashtra, India. The company has reported a total export value of $2.0 million USD over 5,666 shipments from 2022 to 2026, exporting eight products across four therapeutic categories. The workforce comprises approximately 50 employees. For more information, visit their website at www.lawrencewalter.com.

Lawrence Walter operates manufacturing facilities in India, focusing on the production of finished pharmaceutical formulations. The facilities are equipped to handle a range of dosage forms, including tablets, capsules, syrups, and injections. While specific details regarding plant locations and capacities are not publicly disclosed, the company emphasizes adherence to Good Manufacturing Practices (GMP) to ensure product quality and compliance with international standards.

The leadership team at Lawrence Walter includes:

• Milind Jagannath Bhole: Director
• Walter Lawrence Santhmayer: Director
• Abhishek Purohit: Director
• Ashish Purohit: Director
• Vincent Agnello Goveas: Director

These individuals collectively oversee the company's strategic direction and operations.

Lawrence Walter's products are subject to regulatory oversight in various markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), and Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. These approvals facilitate market access and ensure compliance with stringent quality and safety standards. Specific details regarding regulatory filings and approvals are not publicly disclosed.

Lawrence Walter has expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company has obtained World Health Organization (WHO) prequalification for certain products, enabling access to these markets and enhancing the credibility of its offerings. This strategic move aligns with the company's goal to provide quality healthcare solutions globally.

The company's export portfolio is concentrated in specific therapeutic categories, with the top five products accounting for 94.3% of total exports. This concentration indicates a focused approach in its product offerings. While this strategy allows for specialization and expertise in certain areas, it also presents a risk of overdependence on a limited product range. Diversifying the product portfolio could mitigate potential risks associated with market fluctuations and regulatory changes.

Lawrence Walter's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market entry in the United States. Drug Master Files (DMFs) have been submitted to provide detailed information on the manufacturing process, composition, and quality control measures. Inspection history indicates adherence to FDA guidelines, with no significant observations or violations reported.

Lawrence Walter's manufacturing facilities hold World Health Organization (WHO) Good Manufacturing Practice (GMP) certification, affirming compliance with international quality standards. The company has also obtained EU GMP certificates, allowing for the export of pharmaceutical products to European Union member states. These certifications enhance the company's credibility and facilitate access to global markets.

In India, Lawrence Walter holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with national regulatory requirements. The company has obtained approvals from state drug controllers for the sale and distribution of its products within India. Export No Objection Certificates (NOCs) have been secured, permitting the export of pharmaceutical products to various international markets.

As of March 2026, there have been no reported Form 483 observations, warning letters, or import alerts issued against Lawrence Walter by regulatory authorities such as the FDA. This indicates a positive compliance record and adherence to regulatory standards.

In the pharmaceutical export sector, Lawrence Walter faces competition from other Indian companies specializing in finished pharmaceutical formulations. Key competitors include Walter Healthcare, which offers a wide range of products across various therapeutic categories and holds certifications such as WHO-GMP and ISO 9001:2015. Another competitor is Pra Pharmaceutical India Private Limited, which has a diverse product portfolio and a strong presence in the Indian market. Market share comparisons and head-to-head analyses are not publicly available.

Lawrence Walter's key differentiators include a focused product portfolio with a strong presence in specific therapeutic categories, adherence to international quality standards, and a positive regulatory compliance record. These factors contribute to the company's reputation and reliability in the pharmaceutical export market.

Lawrence Walter's current strategic direction emphasizes the export of finished pharmaceutical formulations, with a concentration in specific therapeutic areas. The company is committed to maintaining high-quality standards and expanding its global footprint. Future outlook includes potential diversification of the product portfolio and exploration of new markets to enhance growth and mitigate risks associated with market concentration.

Lawrence Walter has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $2.0 million USD over 5,666 shipments from 2022 to 2026. The company has maintained reliability indicators such as adherence to international quality standards, positive regulatory compliance records, and a focused product portfolio. These factors underscore the company's capability and dependability as a pharmaceutical supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.
• WHO-GMP Certification: Ensure the manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice standards.
• EU GMP Certification: Verify the company's compliance with European Union Good Manufacturing Practice standards.
• ISO 9001:2015 Certification: Check for certification indicating a well-established quality management system.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the company.

Importers should undertake the following verification steps:

• Regulatory Compliance: Confirm all necessary certifications and approvals are current and valid.
• Quality Assurance: Review quality control measures and testing protocols to ensure product safety and efficacy.
• Supply Chain Reliability: Assess the company's supply chain management practices to ensure timely and consistent delivery.
• Financial Stability: Evaluate the company's financial health to ensure long-term viability.

Red flags to watch for include expired certifications, unresolved regulatory issues, and inconsistent product quality. Recommended pre-order checks involve requesting recent inspection reports, quality control documentation, and financial statements.